Keun Cheon Kim

Keun Cheon Kim

Auto-generated profile, based on publicly available information

Keun Cheon Kim

University of Missouri School of Medicine 1 Department of Obstetrics, Gynecology and Women's Health Columbia, MO 65203

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2020 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
ELEun Ju Lee
Eun Ju Lee
IHInjoo Hwang
Injoo Hwang
JLJi Yeon Lee
Ji Yeon Lee
JPJong Nam Park
Jong Nam Park
KKKeun Cheon Kim
Keun Cheon Kim
HKHyoSoo Kim
HyoSoo Kim
Transforming growth factor β (TGFβ) is a crucial factor in fibrosis, and transcriptional intermediary factor 1γ (TIF1γ) is a negative regulator of the TGFβ pathway; however, its role in liver fibrosis is unknown. In this study, mesenchymal stem cells derived from human embryonic stem cells (hE-MSCs) that secrete hepatocyte growth factor (HGF) were used to observe the repair of thioacetamide (TAA)-induced liver fibrosis. Our results showed that TIF1γ was significantly decreased in LX2 cells when exposed to TGFβ1. Such decrease of TIF1γ was significantly prevented by co-culture with hE-MSCs. Interaction of TIF1γ with SMAD2/3 and binding to the promoter of the α-smooth muscle gene (αSMA) suppressed αSMA expression. Phosphorylation of cAMP response element–binding protein (CREB) and binding on the TIF1γ promoter region induced TIF1γ expression. Furthermore, hepatic stellate cell–specific TIF1γ-knockout mice showed aggravation of liver fibrosis. In conclusion, loss of TIF1γ aggravates fibrosis, suggesting that a strategy to maintain TIF1γ during liver injury would be a promising therapeutic approach to prevent or reverse liver fibrosis.

18 June 2026 in Disease Models & Mechanisms
Verified
Journal Article
Open access
SNShamsun Nahar
Shamsun Nahar
EJEunhee M. Jeong
Eunhee M. Jeong
KKKeun Cheon Kim
Keun Cheon Kim
RBRussell R. Broaddus
Russell R. Broaddus
JYJUNG-YOON YOO
JUNG-YOON YOO
Tai-hoon KimTai-hoon Kim
Tai-hoon Kim
Endometrioid endometrial cancer (EEC) is the most prevalent gynecological malignancy. While early-stage EEC typically carries a favorable prognosis, late-stage EEC shows significantly poorer outcomes, with a five-year survival rate of only 17−19%. Co-occurring PTEN and CTNNB1 variants are frequent in EEC and linked to poor prognosis. To investigate their functional impact, we generated uterine-specific Pten knockout mice and dominantly stabilized Ctnnb1 mutant mice (Pgrcre/+Ptenf/fCtnnb1f(ex3)/+; Ptend/dCtnnb1f(ex3)/+). These double-mutant mice exhibited significantly reduced survival compared to single Pten knockout (Pgrcre/+Ptenf/f; Ptend/d) mice. Histopathology revealed aggressive, metastatic endometrioid cancer in Ptend/dCtnnb1f(ex3)/+ mice; these mice developed myometrial invasion by four weeks of age – unlike Ptend/d mice. Transcriptomic analysis identified activation of multiple oncogenic pathways, including WNT/CTNNB1, PI3K/AKT, basal cell carcinoma, sonic hedgehog signaling and epithelial−mesenchymal transition (EMT). Immunohistochemistry confirmed hallmark features of EMT in the uterus of double-mutant mice, including strong downregulation of E-cadherin (CDH1) and upregulation of the EMT regulator SNAIL (Snai1). These findings demonstrate that synergistic mutations of PTEN and CTNNB1 promote early invasion, EMT activation, and metastatic progression, offering mechanistic insight into the aggressive behavior and poor clinical outcomes associated with this subtype of EEC.

31 March 2022 in Journal of Animal Reproduction and Biotechnology
Verified
Journal Article
Open access
PDF file
YLYoung Jae Lee
Young Jae Lee
KKKeun Cheon Kim
Keun Cheon Kim
JLJeong Mook Lim
Jeong Mook Lim
SLSeung Tae Lee
Seung Tae Lee

1 August 2025 in In Vitro Cellular & Developmental Biology - Animal
Verified
Journal Article
Closed access
PDF file
JLJeong Min Lee
Jeong Min Lee
HLHyun Lee
Hyun Lee
YJYe Rin Jeon
Ye Rin Jeon
KKKeun Cheon Kim
Keun Cheon Kim
YLYoung Jae Lee
Young Jae Lee
SLSeung Tae Lee
Seung Tae Lee

12 October 2026 in Current Molecular Medicine
Verified
Journal Article
Closed access
PDF file
KDKrystina Dunston
Krystina Dunston
KKKeun Cheon Kim
Keun Cheon Kim
SNShamsun Nahar
Shamsun Nahar
JYJUNG-YOON YOO
JUNG-YOON YOO
AHAmanda Hull
Amanda Hull
Tai-hoon KimTai-hoon Kim
Tai-hoon Kim
Introduction: Endometrial Cancer (EC) is the most prevalent gynecologic malignancy, and its incidence continues to rise globally. PTEN mutations occur frequently in EC and lead to aberrant activation of the PI3K/AKT pathway, driving uncontrolled cellular proliferation and survival. In murine models, uterine-specific deletion of Pten results in rapid EC development. Emerging evidence implicates Histone Deacetylases (HDACs) as key epigenetic regulators of tumor progression, yet the specific role of HDAC3 in EC remains poorly defined. Methods: We generated uterine-specific Pten and Hdac3 double-knockout mice (Pgrcre/+Hdac3f/fPtenf/f; Hdac3d/dPtend/d) to investigate the functional and therapeutic relevance of HDAC3. Histopathologic analysis was performed to examine the effect of Hdac3 ablation on EC with Pten deficiency compared with Pten single-knockout mice (Pgrcre/+Ptenf/f; Ptend/d) at 1 and 2 months of age. To evaluate the effect of the HDAC3 inhibitor (RGFP966), 6-week-old Ptend/d (Stage Ⅰ EC) mice were treated with vehicle or RGFP966 (10 mg/kg) twice per week for 5 weeks via intraperitoneal injection. Results: Histopathological analysis revealed marked regression of EC in Hdac3d/dPtend/d mice compared to Ptend/d controls to investigate the functional and therapeutic relevance of HDAC3. Pharmacologic inhibition of HDAC3 using the selective inhibitor RGFP966 in Ptend/d mice significantly reduced tumor burden and metastatic dissemination compared to vehicle treatment. Mechanistically, HDAC3 inhibition suppressed tumor cell proliferation and enhanced apoptosis, concomitant with reduced phosphorylation of ERK1/2 and AKT levels. Discussion: While our findings demonstrate significant antitumor effects of HDAC3 inhibition in PTEN-deficient endometrial cancer, further studies are needed to define the downstream molecular pathways responsible for these effects. Conclusion: Collectively, these findings establish HDAC3 as a critical epigenetic driver of endometrial tumorigenesis and support selective HDAC3 inhibition as a promising therapeutic strategy for PTEN-deficient EC.